Amphastar Pharmaceuticals logo

Amphastar PharmaceuticalsNASDAQ: AMPH

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 June 2014

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.15 B
-31%vs. 3y high
81%vs. sector
-54%vs. 3y high
21%vs. sector
-44%vs. 3y high
68%vs. sector
-48%vs. 3y high
48%vs. sector

Price

regular market | 11 min ago
$44.63+$0.55(+1.24%)

Dividend

No data over the past 3 years
$191.21 M$192.69 M
$191.21 M$40.43 M

Analysts recommendations

Institutional Ownership

AMPH Latest News

Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates
zacks.com06 November 2024 Sentiment: NEUTRAL

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago.

Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com30 October 2024 Sentiment: POSITIVE

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
zacks.com25 October 2024 Sentiment: POSITIVE

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?
zacks.com18 October 2024 Sentiment: POSITIVE

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amphastar Pharmaceuticals Offers Interesting Growth And Income Prospects
seekingalpha.com13 September 2024 Sentiment: POSITIVE

Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene MIST. The company's solid balance sheet, with a current ratio of 3.52 and manageable debt levels, provides flexibility to navigate market changes. Risks include reliance on single-source supplies, dependency on Lilly for BAQSIMI manufacturing, and the impact of reference brand demand on generic products.

Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
accesswire.com28 August 2024 Sentiment: POSITIVE

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

6 Beaten Down Stocks Rated Buy (SA Quant)
seekingalpha.com19 August 2024 Sentiment: POSITIVE

The three-week market selloff sparked by recession fears was led by plunging tech, cyclical, industrial, and energy stocks. High-quality stocks clobbered in the past 30 days, and others beaten down in the past year offer potential buying opportunities. We identified 6 stocks down by double digits within the last year with Buy or Strong Buy Quant Ratings, high forward growth metrics, and attractive valuations.

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2024 Earnings Call Transcript
seekingalpha.com09 August 2024 Sentiment: NEUTRAL

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer Tony Marrs - Executive Vice President, Regulatory Affairs and Clinical Operations Conference Call Participants Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Jason Gerberry - Bank of America Tim Chiang - Capital One Serge Belanger - Needham & Company Glen Santangelo - Jefferies Operator Greetings, and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Call. At this time, all participants are in a listen-only mode.

Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates
zacks.com07 August 2024 Sentiment: POSITIVE

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.65 per share a year ago.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
accesswire.com07 August 2024 Sentiment: POSITIVE

Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024. Second Quarter Highlights Net revenues of $182.4 million for the second quarter GAAP net income of $37.9 million, or $0.73 per share, for the second quarter Adjusted non-GAAP net income of $48.7 million, or $0.94 per share, for the second quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "As we finish another strong quarter, Amphastar has continued its impressive performance with solid sales growth.

What type of business is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

What sector is Amphastar Pharmaceuticals in?

Amphastar Pharmaceuticals is in the Healthcare sector

What industry is Amphastar Pharmaceuticals in?

Amphastar Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Amphastar Pharmaceuticals from?

Amphastar Pharmaceuticals is headquartered in United States

When did Amphastar Pharmaceuticals go public?

Amphastar Pharmaceuticals initial public offering (IPO) was on 25 June 2014

What is Amphastar Pharmaceuticals website?

https://www.amphastar.com

Is Amphastar Pharmaceuticals in the S&P 500?

No, Amphastar Pharmaceuticals is not included in the S&P 500 index

Is Amphastar Pharmaceuticals in the NASDAQ 100?

No, Amphastar Pharmaceuticals is not included in the NASDAQ 100 index

Is Amphastar Pharmaceuticals in the Dow Jones?

No, Amphastar Pharmaceuticals is not included in the Dow Jones index

When was Amphastar Pharmaceuticals the previous earnings report?

No data

When does Amphastar Pharmaceuticals earnings report?

The next expected earnings date for Amphastar Pharmaceuticals is 28 February 2025